Frequently asked questions
The ELEVECTA™ cell line portfolio, based on an HEK293 cell line, combines innovative design and deep expertise to deliver transient, packaging, and producer options that provide competitive performance, high quality, and flexibility for your AAV production.
ELEVECTA transient cell line preserves flexibility while delivering excellent performance and quality – all aimed at quickly advancing candidates to clinical trials.
Download our app note
See the datafile
ELEVECTA packaging cell line contains all genes except the transgene. It streamlines the screening of assets that use the same capsid to target the same tissue type.
ELEVECTA producer cell line contains all genes to produce AAV – simply induce. The result is a simplified, robust upstream process that easily scales.
Watch this quick video
Explore the data in this whitepaper
In addition to the ELEVECTA cell line portfolio, Cytiva offers a solution tailored for adenovirus vector production with its proprietary CAP™ Ad cell line that minimizes replication-competent adenovirus (RCA) formation.
Read this whitepaper